<DOC>
	<DOCNO>NCT02613182</DOCNO>
	<brief_summary>The rationale study provide additional treatment NEOD001 subject complete Study NEOD001-001 , continue evaluate long term safety tolerability . All subject current NEOD001 trial dose 24 mg/kg , continue study .</brief_summary>
	<brief_title>Open-label Extension Study NEOD001 Subjects With Light Chain ( AL ) Amyloidosis</brief_title>
	<detailed_description>The rationale study provide additional treatment NEOD001 subject complete Study NEOD001-001 , continue evaluate long term safety tolerability . All subject current NEOD001 trial dose 24 mg/kg , continue study . The primary objective study evaluate long-term safety tolerability NEOD001 secondary objective assess immunogenicity NEOD001 incorporate serum NEOD001 concentration population pharmacokinetic ( PK ) analysis .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>1 . Previously enrol treat least 9 month Study NEOD001001 2 . Ability understand willingness sign inform consent form prior initiation study procedures 3 . Has adequate bone marrow reserve , hepatic renal function , demonstrate : Absolute neutrophil count ( ANC ) ≥1.0 ×109/L Platelet count ≥75 × 109/L Hemoglobin ≥9 g/dL Total bilirubin ≤2 time upper limit normal ( × ULN ) Aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) ≤3 × ULN Estimated glomerular filtration rate ≥30 mL/minute 4 . Seated systolic blood pressure 90 180 mmHg 5 . ECOG Performance Status 0 2 6 . Women childbearing potential ( WOCBP ) must negative serum pregnancy test within 28 day prior first administration study drug agree use highly effective physicianapproved contraception 30 day prior first study drug administration 90 day follow last study drug administration 7 . Male subject must surgically sterile must agree use highly effective physicianapproved contraception 30 day prior first study drug administration 90 day follow last study drug administration 1 . Any new medical contraindication clinically significant abnormality physical , neurological , laboratory , vital sign , electrocardiogram ( ECG ) examination ( e.g. , atrial fibrillation ; exception subject ventricular rate control ) precludes continue initiation treatment NEOD001 participation study 2 . History Grade ≥3 infusionassociated adverse event ( AEs ) hypersensitivities NEOD001 excipients 3 . Treatment anticancer therapy ( standard investigational ) within 14 day prior first dose study drug . In addition , subject must fully recover ( i.e. , National Cancer Institute Common Terminology Criteria Adverse Events [ CTCAE ] Grade 1 [ exception : subject prior bortezomib may CTCAE Grade 2 neuropathy ] ) clinically significant toxic effect treatment 4 . Received follow within specified time frame prior first administration study drug : Hematopoietic growth factor , transfusion blood blood product within 1 week Major surgery within 2 week Radiotherapy within 2 week Transplant within 8 week Investigational drug NEOD001 within 4 week Another experimental antiamyloid therapy NEOD001 within 2 year 5 . Uncontrolled symptomatic orthostatic hypotension 6 . Myocardial infarction , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia , within 6 month prior first dose study drug 7 . Uncontrolled infection 8 . Secondary malignancy , exception : Adequately treat basal cell carcinoma , squamous cell carcinoma , situ cervical cancer Adequately treat stage I cancer subject currently remission Any cancer subject diseasefree ≥3 year 9 . Uncontrolled human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C infection 10 . Women lactate</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>